Subscribe
lilly-logo-2--1
Photo: Courtesy of Eli Lilly
23 August 2016Americas

AstraZeneca and Eli Lilly’s Alzheimer’s treatment to be fast tracked

AstraZeneca and Eli Lilly have received US Food and Drug Administration (FDA) fast track designation for the development of a treatment for Alzheimer’s.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Eli Lilly’s Dermira accuses Perrigo of infringing patents
22 October 2020   Pharmaceutical company Eli Lilly’s subsidiary Dermira has accused generic drugmaker Perrigo of infringing eight patents for Qbrexza, a prescription-only cloth towelette approved to treat hyperhidrosis, a condition that causes excessive underarm sweating.
Americas
PTAB grants inter partes review of China’s firm’s Alzheimer’s patent
22 July 2021   The US Patent Trial and Appeal Board has given the go-ahead for an inter partes review of a Chinese pharma company’s US patent related to a treatment for Alzheimer’s.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Eli Lilly’s Dermira accuses Perrigo of infringing patents
22 October 2020   Pharmaceutical company Eli Lilly’s subsidiary Dermira has accused generic drugmaker Perrigo of infringing eight patents for Qbrexza, a prescription-only cloth towelette approved to treat hyperhidrosis, a condition that causes excessive underarm sweating.
Americas
PTAB grants inter partes review of China’s firm’s Alzheimer’s patent
22 July 2021   The US Patent Trial and Appeal Board has given the go-ahead for an inter partes review of a Chinese pharma company’s US patent related to a treatment for Alzheimer’s.

More on this story

Americas
Eli Lilly’s Dermira accuses Perrigo of infringing patents
22 October 2020   Pharmaceutical company Eli Lilly’s subsidiary Dermira has accused generic drugmaker Perrigo of infringing eight patents for Qbrexza, a prescription-only cloth towelette approved to treat hyperhidrosis, a condition that causes excessive underarm sweating.
Americas
PTAB grants inter partes review of China’s firm’s Alzheimer’s patent
22 July 2021   The US Patent Trial and Appeal Board has given the go-ahead for an inter partes review of a Chinese pharma company’s US patent related to a treatment for Alzheimer’s.

More features

Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott
‘A marathon and a sprint at the same time’: How we won $452m damages